



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING	G DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/717,101	11/19/2003		Harold L. Atkins	18013-C1	7313
31976	7590	08/25/2004		EXAMINER	
LEWIS J. KREISLER LEGAL DEPARTMENT 930 CLOPPER ROAD				LI, BAO Q	
				ART UNIT	PAPER NUMBER
GAITHERSB	BURG, MD	20878		1648	

Please find below and/or attached an Office communication concerning this application or proceeding.

	3	Application No.	Applicant/a)
,		Application No.	Applicant(s)
	Office Action Summary	10/717,101	ATKINS ET AL.
	Office Action Summary	Examiner	Art Unit
	The MAN INC DATE And	Bao Qun Li	1648
Period f	The MAILING DATE of this communication of or Reply	appears on the cover sheet w	vith the correspondence address
THE - Extraction - If th - If N - Fail	MAILING DATE OF THIS COMMUNICATION Ensions of time may be available under the provisions of 37 CFR or SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a compared period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by start reply received by the Office later than three months after the manned patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a reply within the statutory minimum of the field will apply and will expire SIX (6) MC tute, cause the application to become A	reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133)
Status			
1)🖂	Responsive to communication(s) filed on 02	<u> March 2004</u> .	
2a)[This action is FINAL . 2b) ☐ T	his action is non-final.	
3)□	Since this application is in condition for allow closed in accordance with the practice unde		
Disposit	ion of Claims		
5)□ 6)□ 7)□ 8)⊠ Applicat	Claim(s) 1-24 is/are pending in the application 4a) Of the above claim(s) is/are with definition and/or claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-24 are subject to restriction and/or ion Papers The application is objected to but the Eventine i	rawn from consideration. or election requirement.	
	The specification is objected to by the Exami		houth a Formation
10)	The drawing(s) filed on is/are: a) a applicant may not request that any objection to the		
	Replacement drawing sheet(s) including the corre		
11)	The oath or declaration is objected to by the		• •
	under 35 U.S.C. § 119		
12)[a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure See the attached detailed Office action for a list	ents have been received. Ints have been received in Antionity documents have been eau (PCT Rule 17.2(a)).	application No received in this National Stage
Attachmen	t(s)		
l) 🔲 Notic	e of References Cited (PTO-892)	4) Interview S	Summary (PTO-413)
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date
	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 r No(s)/Mail Date	8) 5) Notice of I 6) Other:	nformal Patent Application (PTO-152) —·

Application/Control Number: 10/717,101

Art Unit: 1648

DETAILED ACTION

Claims 1-24 are pending.

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-21, drawn to a method of reducing neoplastic cell ex vivo by contacting mixture of normal hematopoeitic cells with neoplastic cell, classified in class 435, subclass 235.1.
 - II. Claims 22-24, drawn to a method of treating cancer ex vivo comprising contacting the mixture of neoplastic cells and bone marrow cells with an RNA virus plus amyoloabltic treatment, classified in class 424, subclass 93.1.

Upon election group I, a further restriction is required under 35 U.S.C. 121:

- A. The RNA virus is a single stranded RNA virus.
- B. The RNA virus is a double stranded RNA virus.

Upon election group A, a further restriction is required under 35 U.S.C. 121:

- i. The single stranded RNA virus is a rhabdovirus.
- ii. The single stranded RNA virus is a paramyxovirus.
- iii. The single stranded RNA virus is a Sindbis virus.
- 2. Claim 2 link(s) inventions of group A and Group B, The restriction requirement of groups A and B when the linked inventions is subject to the nonallowance of the linking claim(s), claim 2. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Application/Control Number: 10/717,101 Page 3

Art Unit: 1648

3. Claim 6 link(s) inventions of groups i-ii and iii. The restriction requirement of groups i to iii when the linked inventions is subject to the nonallowance of the linking claim(s), claim 6. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

The inventions are distinct, each from the other because of the following reasons:

Inventions of groups of i to iii are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to different methods by using structurally and functionally different viruses and that they are not disclosed as capable of use together, e.g. the method of Group i uses rhabdovirus, whereas the method of the group ii uses paramyxovirus.

Inventions of groups of A to B are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to different methods by using structurally and functionally different viruses and that they are not disclosed as capable of use together, e.g. the method of Group A uses a single stranded RNA virus, whereas the method of the group ii uses double stranded virus.

Inventions of groups of I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to different methods comprising different

Art Unit: 1648

procedures by using different agents, e.g. the method of Group I uses virus with inhibiting virus agent, whereas the method of the group II use virus plus cell activation agent.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 571-272-0904. The examiner can normally be reached on 7:00 am to 3:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bao Qun Li Art Unit 1648 August 19, 2004



Page 4